New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and ...

Researchers have developed a dual-pathway computational framework that combines molecular graphs, biological knowledge ...

A review in Molecular Cancer examines how antibody-drug conjugates treat solid tumors while addressing clinical resistance, ...

InflaRx announced the publication of Phase 1 clinical trial results for Izicopan, an experimental oral treatment being developed for inflammatory and immune-related diseases. The ...

Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with ...

Evommune licensed a drug that erases an immune protein to bypass JAK inhibitor warnings; Caldera added a TL1A bispecific from ...

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (Orchestra BioMed or the Company), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations ...

A review led by researchers at the Naval Medical University proposes a structured framework for evaluating plant-derived anti ...

Mondego Bio doses first humans with oral MB-388, an immunotherapy-resistance drug targeting the PTPN2/PTPN1 pathway. Phase 1a ...

Cork startup ArrayPatch builds dissolving microneedles entirely from the drug itself — no polymer — and may put GLP-1 obesity ...

CANTANHEDE, Portugal, Nov 5, 2026 – Portuguese biotechnology company Mondego Bio has initiated its first human clinical trial ...

Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug ...